Indication

Treatment to slow progression of coronary artery disease

Coronary artery disease is a chronic cardiovascular disorder characterized by the gradual accumulation of fibrofatty atherosclerotic plaques within the epicardial coronary arteries. Read more about Treatment to slow progression of coronary artery disease

189 drugs 105 manufacturers

Advertisement

Drugs that treat it

Common Treatment to slow progression of coronary artery disease therapies.

Showing 181–189 of 189 drugs

SIMVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+13
GSMS, INC.

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
SAFECOR HEALTH

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
SAFECOR HEALTH

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
UMEDICA LABORAT

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
TEVA PHARM

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
MACLEODS PHARMA

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
AMICI PHARMA, I

SIMVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+13
APHENA PHARMA S

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
Lannett Company
Filter & compare in the drug finder →Opens the drug finder with Treatment to slow progression of coronary artery disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Treatment to slow progression of coronary artery disease.

Coronary artery disease is a chronic cardiovascular disorder characterized by the gradual accumulation of fibrofatty atherosclerotic plaques within the epicardial coronary arteries.

This process involves lipid retention, chronic vascular inflammation, endothelial dysfunction, and smooth muscle cell proliferation, which progressively narrow the arterial lumen and restrict myocardial perfusion.

Clinically, continuing plaque advancement increases the likelihood of luminal stenosis and plaque instability, which may manifest as chronic stable angina, acute coronary syndromes, ischemic cardiomyopathy, or fatal ischemic events.

Treatment to slow progression of coronary artery disease targets this underlying vascular pathology in affected individuals to inhibit further atheroma growth, stabilize vulnerable plaque architecture, and mitigate long-term adverse ischemic complications.

Personalize your experience

Follow Treatment to slow progression of coronary artery disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it